AS A CONSEQUENCE of its admission to the AIM Market, UK polymer company Revolymer has appointed Julian Heslop to its board as a non-executive director.
Heslop served as CFO of GlaxoSmithKline between April 2005 and March 2011. He was also Chairman of ViiV Healthcare until March 2011.
He served as senior vice president, operations controller of GSK between January 2001 and March 2005 and as financial controller of Glaxo Wellcome from April 1998 to December 2000.
Previously, Heslop had senior finance roles at Grand Metropolitan and Imperial Brewing and Leisure.
He is a fellow of the ICAEW.
Revolymer placed shares onto the exchange to raise £25m from institutional investors, and its market cap at the time of its listing will be approxiamtely £53m. The proceeds will be used to expand its distribution of its confectionary gum products in the US and Europe, fund regulatory documentation around the nicotine gum industry, and develop new products.
Its share price is 103.5p in this morning’s trading.
For more company and market information visit the Share Price Centre
The application of robotics in finance functions is moving faster than predicted. Although, companies are cautious in how they are applying artificial intelligence to ensure results first, many are stepping up their investigations
EU competition commissioner Margrethe Vestager has defended the decision to order technology giant Apple to pay €13bn (£11bn) in back taxes to the Irish government
Carillion has announced the appointment of a new finance director as it reported a rise in first half profits and sales led by strong growth in its support services business
The UK inflation rate hit its highest level in almost two years in July, suggesting that the sharp fall in sterling following the UK referendum to leave the European Union is forcing prices up